ArticleNature immunology2023
Hallmarks of CD8
Abstract read
In one paragraph
Article in Nature immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed.
- HBsAg-tagged tumour vaccine system eliminates solid tumours through virus-specific memory T cells.Nature biomedical engineering · 2026Article
- Risk Factors for Secondary Immunodeficiency in the Aged.The journal of allergy and clinical immunology. In practice · 2026Review
- Targeting ABL kinases overcomes melanoma immune evasion following resistance to MAPK inhibition.Nature communications · 2026Article
- DNA Hypomethylating Agents Preserve T-cell Stemness and Potentiate the Efficacy of CD3-Bispecific Antibodies.Cancer immunology research · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- New insights into progenitor exhausted T cell populations.Nature reviews. Immunology · 2026Article
- The atypical IκB factor IκBδ enhances CD8 T cell accumulation and effector functions in solid tumors.bioRxiv : the preprint server for biology · 2026Article
- Avoidance of MAIT cells is an essential determinant ofProceedings of the National Academy of Sciences of the United States of America · 2026Article
- T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Exhausted T cell phenotypes in disseminated coccidioidomycosis.JCI insight · 2026Article
- Article
- CKS1B is a tumor-intrinsic factor driving CD8Science advances · 2026Article
- Adoptive T-cell therapies in the clinic.Bioengineering & translational medicine · 2026Review
- Tumor-immune trajectory context connects static tissue architecture to clinical outcomes.bioRxiv : the preprint server for biology · 2026Article
- Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases.Precision clinical medicine · 2026Review
- Consequences of the perivascular niche remodeling for tumoricidal T-cell trafficking into metastasis of ovarian cancer.ImmunoHorizons · 2026Article
- Reversible control of T cell exhaustion by NR4A transcription factors revealed through targeted protein degradation.bioRxiv : the preprint server for biology · 2026Article
- Regulators of CD8Nature reviews. Immunology · 2026Review
- Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms.Journal for immunotherapy of cancer · 2026Review
- Immune evasion driven by lipid metabolic reprogramming in endocrine-resistant HRFrontiers in immunology · 2026Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Michael W RudloffDepartment of Medicine, Division of Hematology and Oncology, Department of Pathology, Microbiology, and Immunology, Vanderbilt School of Medicine, Nashville, TN, USA.
Paul ZumboDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
Natalie R FavretDepartment of Medicine, Division of Hematology and Oncology, Department of Pathology, Microbiology, and Immunology, Vanderbilt School of Medicine, Nashville, TN, USA.
Jessica J RoetmanDepartment of Medicine, Division of Hematology and Oncology, Department of Pathology, Microbiology, and Immunology, Vanderbilt School of Medicine, Nashville, TN, USA.
Carlos R Detrés RománDepartment of Medicine, Division of Hematology and Oncology, Department of Pathology, Microbiology, and Immunology, Vanderbilt School of Medicine, Nashville, TN, USA.
Megan M ErwinDepartment of Medicine, Division of Hematology and Oncology, Department of Pathology, Microbiology, and Immunology, Vanderbilt School of Medicine, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-7014-0856
Kristen A MurrayDepartment of Medicine, Division of Hematology and Oncology, Department of Pathology, Microbiology, and Immunology, Vanderbilt School of Medicine, Nashville, TN, USA.
Sriya T JonnakutiDepartment of Medicine, Division of Hematology and Oncology, Department of Pathology, Microbiology, and Immunology, Vanderbilt School of Medicine, Nashville, TN, USA.
Friederike DündarDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-2301-112X
Doron BetelApplied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-8006-7752
Mary PhilipDepartment of Medicine, Division of Hematology and Oncology, Department of Pathology, Microbiology, and Immunology, Vanderbilt School of Medicine, Nashville, TN, USA. mary.philip@vumc.org.ORCID http://orcid.org/0000-0001-7496-2630
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3MShop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 1989 to 2026
$19.6MMULTIDISCIPLINARY BASIC RESEARCH TRAINING IN CANCERT32CA009592 · NCI · VANDERBILT UNIVERSITY · PI Justin M Balko, Julie A Rhoades (Sterling) · 1987 to 2026
$10.4MVANTAGE:Consolidation to create the Vanderbilt Technologies for Advanced GenomicsG20RR030956 · NCRR · VANDERBILT UNIVERSITY · PI PIETENPOL, JENNIFER A · 2010 to 2010
$8.7MTRAINING PROGRAM IN CELLULAR, BIOCHEMICAL, &MOLECULAR ST32GM008554 · NIGMS · VANDERBILT UNIVERSITY · PI PATTON, JAMES G. · 1995 to 2020
$7.4MMedical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8MInterdisciplinary Training in Rheumatic DiseasesT32AR059039 · NIAMS · VANDERBILT UNIVERSITY · PI Tracy Minan Frech, AMY S MAJOR · 2010 to 2026
$4.3MTCR signaling and cell cycle regulation in tumor-specific CD8 T cell dysfunctionR37CA263614 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Mary Philip · 2022 to 2026
$2.7MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA098131NCI NIH HHS R37 CA263614NCI NIH HHS T32 CA009592NCRR NIH HHS G20 RR030956NEI NIH HHS P30 EY008126NIAMS NIH HHS T32 AR059039NIDDK NIH HHS P30 DK058404NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM008554NIGMS NIH HHS T32 GM152284
Abstract
Tumor-specific CD8+ T cells (TST) in patients with cancer are dysfunctional and unable to halt cancer progression. TST dysfunction, also known as exhaustion, is thought to be driven by chronic T cell antigen receptor (TCR) stimulation over days to weeks. However, we know little about the interplay between CD8
Indexed as
CD8-Positive T-LymphocytesNeoplasmsAnimalsAntigens, NeoplasmCell DivisionChromatinMiceReceptors, Antigen, T-CellAntigens, NeoplasmChromatinReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.